MIP
TAK icon

Mondrian Investment Partners’s Takeda Pharmaceutical TAK Stock Holding History

Mondrian Investment Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-299
Closed -$4.66K – 108
2025
Q4 		$4.66K Sell
299
-521
-64% -$7.45K ﹤0.01% 99
2025
Q3 		$12K Buy
+820
New +$12.2K ﹤0.01% 94
2025
Q1 		$21.4K Sell
1,438
-104
-7% -$1.46K ﹤0.01% 94
2024
Q4 		$20K Sell
1,542
-5,092,913
-100% -$70M ﹤0.01% 96
2024
Q3 		$71.3M Sell
5,094,455
-2,644,293
-34% -$37.5M 1.08% 44
2024
Q2 		$108M Sell
7,738,748
-4,341,214
-36% -$57.5M 1.67% 34
2024
Q1 		$169M Buy
12,079,962
+3,912,569
+48% +$56.9M 2.32% 13
2023
Q4 		$117M Buy
8,167,393
+4,085,678
+100% +$58M 1.84% 28
2023
Q3 		$61.2M Hold
4,081,715
– – 1.26% 42
2023
Q2 		$64.1M Hold
4,081,715
– – 1.28% 39
2023
Q1 		$67.3M Sell
4,081,715
-286,000
-7% -$4.56M 1.48% 32
2022
Q4 		$69.9M Sell
4,367,715
-384,000
-8% -$5.36M 1.55% 30
2022
Q3 		$61.8M Hold
4,751,715
– – 1.35% 30
2022
Q2 		$66.5M Buy
4,751,715
+432,000
+10% +$6.17M 1.39% 33
2022
Q1 		$60.5M Buy
4,319,715
+261,000
+6% +$3.83M 1.24% 37
2021
Q4 		$56.8M Buy
4,058,715
+355,311
+10% +$4.98M 1.12% 36
2021
Q3 		$59.3M Hold
3,703,404
– – 1.2% 32
2021
Q2 		$63M Buy
3,703,404
+193,000
+5% +$3.29M 1.2% 30
2021
Q1 		$59.7M Buy
3,510,404
+235,744
+7% +$4.24M 1.28% 31
2020
Q4 		$58.9M Buy
3,274,660
+225,186
+7% +$3.95M 1.46% 26
2020
Q3 		$45.7M Buy
3,049,474
+19,828
+0.7% +$361K 1.58% 21
2020
Q2 		$54.5M Sell
3,029,646
-399,524
-12% -$7.17M 1.95% 17
2020
Q1 		$51.4M Sell
3,429,170
-210,000
-6% -$3.81M 1.8% 15
2019
Q4 		$72.8M Hold
3,639,170
– – 1.91% 12
2019
Q3 		$61.9M Buy
3,639,170
+229,000
+7% +$3.96M 2% 11
2019
Q2 		$61.4M Buy
3,410,170
+397,300
+13% +$7.23M 1.96% 17
2019
Q1 		$60.3M Buy
3,012,870
+139,000
+5% +$2.8M 1.9% 20
2018
Q4 		$48.9M Buy
+2,873,870
New +$48.5M 1.79% 22

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mondrian Investment Partners's TAK Position: Q1 2026 in Review

Mondrian Investment Partners sold out of Takeda Pharmaceutical (TAK) in Q1 2026, closing a stake of 299 shares — an estimated $4.66K sold.

Mondrian Investment Partners first reported a position in TAK in Q4 2018 and held it in 28 quarters. The position peaked at $169M in Q1 2024. 361 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Mondrian Investment Partners reported no remaining Takeda Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Mondrian Investment Partners sold 299 Takeda Pharmaceutical shares in Q1 2026, an estimated $4.66K.
  • Mondrian Investment Partners first reported a position in Takeda Pharmaceutical in Q4 2018 and held it in 28 quarters.
  • Mondrian Investment Partners's Takeda Pharmaceutical position peaked at $169M in Q1 2024.
  • 361 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Mondrian Investment Partners's 13F filing for Q1 2026, filed 29 Apr 2026.